139/19 – Information regarding the rights issue from RhoVac AB
RhoVac's reports positive results from the 12 months follow-up of the company's phase I/II clinical study
Market Notice 56/22 - Last day of trading in RhoVac AB's BTU
Technical Analysis | Spotlight
RhoVac AB will be transferred to Spotlight Stock Market's observation list
spotlight_group_logo_cmyk.png
Share Information | Chosa Oncology
RhoVac receives approval in Sweden to start clinical phase IIb trial
The Canadian Intellectual Property Office intends to grant RhoVac's patent application for RV001 (onilcamotide) cancer vaccine
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer
Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List
RhoVac — Stopping metastasis in its tracks - Edison Group
RhoVac aktie (RHOVAC) | Alla nyheter, analys, riktkurs… - Börskollen
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac's events during May - August
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac Participates in BIO Europe Digital
RhoVac Confirms Forecast – BRaVac Phase IIb study recruitment to close in Quarter 3 2021
RhoVac — Good execution in challenging times for industry - Edison Group
RhoVac aktie (RHOVAC) | Alla nyheter, analys, riktkurs… - Börskollen
RhoVac receives FDA approval in the US for the start of its Phase IIb clinical trial
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac AB (under name change to Chosa Oncology AB) - Stock and Shares News | IPO HUB
RhoVac — Good execution in challenging times for industry - Edison Group
